Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741147 | 0.90 | DPP4 (0.36) | DPP4DPP8HRH3KCNH2MEN1 | |
| SCHEMBL6739759 | 0.86 | GPR119 (0.35) | GPR119HRH3KCNH2AR | |
| SCHEMBL6736898 | 0.85 | GPR119 (0.34) | GPR119HRH3KCNH2AR | |
| SCHEMBL6737084 | 0.82 | GPR119 (0.33) | GPR119KCNH2 | |
| SCHEMBL6742543 | 0.79 | KCNH2 (0.39) | GPR119DPP4DPP8KCNH2MEN1 | |
| SCHEMBL6738989 | 0.76 | DPP4 (0.41) | DPP4DPP8HRH3KCNH2MEN1 | |
| SCHEMBL6737930 | 0.74 | CHRNA7 (0.36) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL6741138 | 0.73 | KCNH2 (0.40) | DPP4DPP8HRH3KCNH2MEN1 | |
| SCHEMBL6734913 | 0.73 | KCNH2 (0.33) | HRH3KCNH2 | |
| SCHEMBL6733200 | 0.73 | KDM1A (0.37) | GPR119KCNH2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | GPR119 1522/4885DPP4 3029/4885DPP8 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.